TABLE 1.
Baseline characteristics of included patients (T0)
| Characteristic | Glioma (n = 263) | Meningioma (n = 242) | Total (n = 505) | |||
|---|---|---|---|---|---|---|
| ε4 carrier (n = 64) | Non‐carrier (n = 199) | ε4 carrier (n = 64) | Non‐carrier (n = 178) | ε4 carrier (n = 128) | Non‐carrier (n = 377) | |
| Sociodemographic | ||||||
| Age, M ± SD | 53.2 ± 14.8 | 53.2 ± 13.8 | 55.9 ± 12.7 | 57.0 ± 11.6 | 54.9 ± 13.9 | 55.3 ± 13.1 |
| Female, n (%) | 28 (44) | 71 (36) | 41 (64) | 135 (76) | 69 (54) | 206 (55) |
| Education, n (%) | ||||||
| Low | 20 (31) | 57 (29) | 25 (39) | 63 (35) | 45 (35) | 120 (32) |
| Middle | 19 (30) | 69 (34) | 14 (22) | 57 (32) | 40 (31) | 126 (33) |
| High | 25 (39) | 73 (37) | 25 (39) | 58 (33) | 43 (34) | 131 (35) |
| Clinical | ||||||
| Diagnosis, n (%) | ||||||
| LGG WHO II | 21 (30) | 59 (30) | n/a | n/a | 19 (15) | 59 (16) |
| HGG WHO III/IV | 45 (70) | 140 (70) | n/a | n/a | 45 (35) | 140 (37) |
| MEN WHO I | n/a | n/a | 61 (95) | 166 (93) | 64 (50) | 178 (47) |
| MEN WHO II | n/a | n/a | 3 (5) | 12 (7) | ||
| Frontal involvement | 34 (53) | 101 (51) | 31 (48) a | 114 (64) a | 65 (51) | 215 (57) |
| Lesion hemisphere | ||||||
| Left | 30 (47) | 81 (40) | 24 (38) | 68 (38) | 54 (42) | 149 (40) |
| Right | 33 (52) | 117 (59) | 36 (56) | 87 (49) | 69 (54) | 204 (54) |
| Bilateral | 1 (1) | 1 (1) | 4 (6) | 23 (13) | 5 (4) | 24 (6) |
| Tumor volume (n = 235), median (range) | 24.0 (15.3–80.1) | 42.8 (2.0–139.1) | 35.1 (30.4–128.2) | 29.5 (4.5–150.2) | 30.9 (3.4–128) | 31.0 (4.5–150) |
| AED use, n (%) | 32 (53) | 83 (43) | 58 (33) | 42 (23) | 47 (38) | 125 (34) |
| Corticosteroid use, n (%) | 29 (48) | 107 (56) | 21 (33) | 15 (23) | 50 (41) | 165 (45) |
| Adjuvant treatment, n (%) | 46 (72) | 146 (73) | 4 (6) | 13 (7) | 50 (39) | 159 (42) |
| Rtx | 46 (72) | 146 (73) | 4 (6) | 13 (7) | 50 (39) | 159 (42) |
| Chtx b | 36 (56) | 117 (59) | 0 (0) | 0 (0) | 36 (29) | 117 (31) |
| Concurrent Rtx Chtx | 36 (56) | 117 (59) | 0 (0) | 0 (0) | 36 (29) | 117 (31) |
| Psychological | ||||||
| HADS anxiety M ± SD | 7.0 ± 4.5 | 6.9 ± 4.3 | 7.1 ± 4.3 | 7.1 ± 4.3 | 7.0 ± 4.4 | 7.0 ± 4.2 |
| HADS depression M ± SD | 5.3 ± 3.7 | 4.8 ± 3.4 | 5.8 ± 4.7 | 6.1 ± 4.9 | 5.6 ± 4.3 | 5.4 ± 4.2 |
Information was available for AED use at T0 n = 124 (ε4 carriers) versus n = 367 (non‐carriers), corticosteroid use at T0 n = 128 versus n = 367 and adjuvant treatment administration n = 126 versus n = 372.
AED, anti‐epileptic drugs; Chtx, chemotherapy; HADS, Hospital Anxiety and Depression Scale; HGG, high‐grade glioma; LGG, low‐grade glioma; MEN, meningioma; n/a, not available; Rtx, radiotherapy; WHO, World Health Organization.
a
Significant difference between carriers and non‐carriers within the diagnostic group (p < 0.05).
b
Temozolomide, lomustine or PCV (procarbazine‐lomustine‐vincristine).